Daiichi Sankyo Acquires U.S. Generic Injectables Maker PharmaForce
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo's U.S. subsidiary, Luitpold Pharmaceutical of New York has fully acquired PharmaForce of Columbus, Ohio, a specialty injectable pharmaceutical company, the Tokyo-based company said
You may also be interested in...
Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008
Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008
Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008.